XLONLLAI
Market cap2mUSD
Dec 23, Last price
9.00GBP
1D
0.00%
1Q
-23.40%
IPO
-95.56%
Name
LungLife AI Inc
Chart & Performance
P/E
—
P/S
6,249.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-45.78%
Revenues
46k
+91.67%
Net income
-5m
L-28.83%
CFO
-5m
L-14.11%
Profile
LungLife AI, Inc., a cancer diagnostics company, develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology. It engages in developing LungLB, an AI enhanced, blood-based test to utilize machine learning to identify and count CTCs with reducing operator hands-on time and increasing test performance. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. The company is based in Thousand Oaks, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 46 91.67% | 24 -87.73% | 196 -4.69% | |||
Cost of revenue | 2,645 | 8,846 | 3,369 | |||
Unusual Expense (Income) | ||||||
NOPBT | (2,599) | (8,822) | (3,174) | |||
NOPBT Margin | ||||||
Operating Taxes | 7 | 4 | 16 | |||
Tax Rate | ||||||
NOPAT | (2,606) | (8,826) | (3,190) | |||
Net income | (5,413) -28.83% | (7,606) 2.17% | (7,444) 32.55% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 2 | 23,444 | ||||
BB yield | ||||||
| Debt | ||||||
Debt current | 233 | 255 | 207 | |||
Long-term debt | 459 | 947 | 1,411 | |||
Deferred revenue | ||||||
Other long-term liabilities | 50 | 50 | 50 | |||
Net debt | (2,136) | (6,808) | (13,011) | |||
| Cash flow | ||||||
Cash from operating activities | (5,020) | (5,845) | (7,539) | |||
CAPEX | (77) | (85) | (1,847) | |||
Cash from investing activities | 4,952 | (115) | (1,796) | |||
Cash from financing activities | (296) | (169) | 23,836 | |||
FCF | (2,429) | (8,626) | (3,492) | |||
| Balance | ||||||
Cash | 2,828 | 8,010 | 14,628 | |||
Long term investments | ||||||
Excess cash | 2,826 | 8,009 | 14,619 | |||
Stockholders' equity | (83,353) | (78,126) | (71,135) | |||
Invested Capital | 91,662 | 91,904 | 92,102 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 25,486 | 25,481 | 15,870 | |||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (2,345) | (8,537) | (2,850) | |||
EV/EBITDA | ||||||
Interest | 41 | 52 | 417 | |||
Interest/NOPBT | ||||||